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A B S T R A C T   
Glycosaminoglycans (GAGs) are long linear sulfated polysaccharides implicated in processes linked to disease 
development such as mucopolysaccharidosis, respiratory failure, cancer, and viral infections, thereby serving as 
potential biomarkers. A successful clinical translation of GAGs as biomarkers depends on the availability of 
standardized GAG measurements. However, owing to the analytical complexity associated with the quantifica-
tion of GAG concentration and structural composition, a standardized method to simultaneously measure mul-
tiple GAGs is missing. In this study, we sought to characterize the analytical performance of a ultra-high- 
performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry (UHPLC-MS/ 
MS)-based kit for the quantification of 17 free GAG disaccharides. The kit showed acceptable linearity, selectivity 
and specificity, accuracy and precision, and analyte stability in the absolute quantification of 15 disaccharides. In 
native human samples, here using urine as a reference matrix, the analytical performance of the kit was 
acceptable for the quantification of CS disaccharides. Intra- and inter-laboratory tests performed in an external 
laboratory demonstrated robust reproducibility of GAG measurements showing that the kit was acceptably 
standardized. In conclusion, these results indicated that the UHPLC-MS/MS kit was standardized for the 
simultaneous measurement of free GAG disaccharides allowing for comparability of measurements and enabling 
translational research.   
1. Introduction 
Glycosaminoglycans (GAGs) are a family of long linear poly-
saccharides consisting of repeating disaccharide units [1]. Different 
structural disaccharides of GAGs have been characterized. In humans, 
the most prevalent classes are chondroitine sulfate (CS) [(→3)-β-D- 
GalNAc(1 → 4)-β-D-GlcA or α-L- IdoA(1 → ], heparan sulfate (HS) 
[(→4)-α-D-GlcNAc or α-D- GlcNS(1 → 4)-β-D-GlcA or α-L-IdoA (1 → ], 
and hyaluronic acid (HA) [(→3)-β-D-GlcNAc(1 → 4)-β-D-GlcA(1 → ] 
where GalNAc is N-acetylgalactosamine, GlcA is glucuronic acid, IdoA is 
iduronic acid, GlcNAc is N-acetylglucosamine, and GlcNS is N-sulfo-
glucosamine. CS and HS disaccharides can each be further modified with 
O-sulfo groups in up to three positions in humans. The modifications 
afford eight different sulfation patterns that modulate the biophysical 
properties of CS and HS in the extracellular matrix. 
This physio-chemical diversity of GAG disaccharides enables highly 
diverse biological functions and implicates GAGs in health- and disease- 
relevant processes such as cell proliferation and wound healing [2,3]. 
For this reason, GAGs showed promise as biomarkers in several diseases, 
like mucopolysaccharidosis [4], respiratory failure [5,6], cancer [7–9], 
and viral infections [10]. 
Precise measurements of GAG concentration and structural compo-
sition at the level of individual GAG disaccharides are crucial for 
structure–function studies on the importance of GAGs in human health 
and disease. Moreover, standardization of GAG measurements is 
imperative for future clinical translation in biomarker discovery. In 
recent years, ultra-high-performance liquid chromatography coupled 
with triple-quadrupole tandem mass spectrometry (UHPLC-MS/MS) 
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emerged as the reference platform for robust and reliable GAG quanti-
fication [11–23]. However, no standardized kit is currently available 
hampering the comparability of findings and translational research. 
Here, we describe a commercially developed kit based on a previ-
ously established method for GAG extraction and detection by Volpi 
et al. [12]. In short, this method relies on the enzymatic depolymer-
ization of GAGs into disaccharides and their subsequent derivatization 
using 2-aminoacridone (AMAC) to improve separation of peaks during 
acquisition of the MS signal. The method was designed to extract spe-
cifically protein-free (or simply “free”) GAGs with no proteolytic step 
during sample preparation. Separation is achieved using ultra-high- 
performance liquid chromatography (UHPLC) and detection using 
electrospray ionization triple-quadrupole mass spectrometry (ESI-MS/ 
MS) through multiple reaction monitoring (MRM) analysis. Even though 
this method has been described extensively in the literature in different 
versions [12,18], a standardized kit based on it is lacking and its 
analytical performance characteristics are unknown. Thus, we sought to 
perform a systematic evaluation of the kit’s analytical performance 
characteristics. 
2. Material and methods 
2.1. Glycosaminoglycan quantification method 
We independently quantified concentrations (in µg mL− 1) of 8 CS 
disaccharides (0s CS, 2s CS, 6s CS, 4s CS, 2s6s CS, 2s4s CS, 4s6s CS, TriS 
Fig. 1. A) Overview of the method described in Volpi et al. [12] on which the UHPLC-MS/MS kit is based on. B) A representative chromatogram for a mixture of 17 
purified disaccharides. The 17 disaccharide peaks are acquired in one multiple reaction monitoring (MRM) run across six different channels (Ch: A to F) based on 
mass transitions associated with analytes. Key − 1: Tris H; 2: Ns6s HS, 3: Ns2S HS, 4: Tris CS; 5: 2s4S CS; 6: 2s6s HS, 7: 2s6s CS, 8: 2s HS, 9: 2s CS, 10: Ns HS, 11: 4s6s 
CS, 12: 6s HS, 13: 4s CS, 14: 6s CS, 15: 0s HS, 16: HA, 17: 0s CS. 
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CS), 8 HS disaccharides (0s HS, 2s HS, 6s HS, Ns HS, Ns6s HS, Ns2s HS, 
2s6s HS, TriS HS) and HA. Also, we calculated the total concentration of 
CS and HS as the sum of the corresponding disaccharide concentrations. 
Unless otherwise specified, we performed GAG extraction, detection, 
and quantification in a single commercial laboratory (reference labo-
ratory, Lablytica Life Science AB, Uppsala, Sweden) using a single lot of 
the commercially produced MIRAM™ Free Glycosaminoglycan Kit 
(Elypta AB, Solna, Sweden). 
The method was performed following MIRAM™ Free Glycosamino-
glycan Kit instructions for use. All reagents, including solvents and 
buffers, and consumables used were contained in the kit, alongside with 
instructions for storage (either room temperature or at − 20 ◦C) and use. 
The kit included enough reagents for processing at least 100 samples. All 
100 samples were prepared at once (no fractional use of the kit, except 
for the inter-laboratory comparison) as in-use stability of the kit was not 
tested as part of the present report. Enzymes were supplied in aqueous 
solution, frozen and aliquoted into 4 tubes for 26 samples each. The 
labelling agent was in powder form, aliquoted into 6 tubes (intended for 
21 samples each). 
This method was based on a previously established protocol for 
glycosaminoglycan (GAG) extraction and detection by Volpi et al. [12] 
(Fig. 1A). Briefly, the method consisted of an enzymatic digestion assay 
using Chondroitinase ABC and Heparinase I-II-III to depolymerize GAGs in 
the sample into disaccharides. Note that the kit did not include pro-
teolytic agents for protein digestion, a step recommended by Volpi et al. 
[12] for certain sample types, thus limiting so depolymerized GAGs to 
the protein-free fraction. Disaccharides were subsequently labeled using 
2-aminoacridone. The samples were then injected into an ultra-high- 
performance liquid chromatography (UHPLC) coupled with electro-
spray ionization triple-quadrupole mass spectrometry system (ESI-MS/ 
MS, Waters® Acquity I-class Plus Xevo TQ-S micro) for disaccharide 
separation and detection. The peaks of the 17 disaccharides were ac-
quired at pre-specified retention times across six transitions using mul-
tiple reaction monitoring (MRM) analysis implemented in the mass 
spectrometry software (Waters® TargetLynx). Software modules pro-
vided in the kit were packaged so that they could be loaded in the mass 
spectrometry software automatically, with all MRM parameters pre- 
specified. We used the mass spectrometry software (Waters® Target-
Lynx) for peak integration, construction of calibration curves, and 
quantification. We exported the results processed data in Excel format 
and imported it into R (4.0.2) for secondary analysis. 
2.2. Analytical performance tests 
We carried out a battery of tests to characterize the linearity, selec-
tivity, specificity, accuracy, precision of the calibrators, carryover, sta-
bility of the calibrators as well as linearity, selectivity, specificity, 
accuracy, precision of the calibrators, stability, recovery, and matrix 
effects intra- and inter-laboratory precision in native samples (see SI 
Methods for detailed experimental descriptions). The tests were 
designed using recommendations from the following CLSI Approved 
Guidelines: C62-A (LC-MS Methods), EP05-A3 (Precision), EP06-A 
(Linearity), EP17-A2 (Detection Capability), EP25-A (Stability), C50-A 
(MS General Principles) C24 (Statistical Quality Control). We pre-
specified acceptance criteria for all tests except for matrix effects (see SI 
Methods for pre-specified acceptance criteria. 
The tests were conducted either on blank samples, standard samples, 
or “proxy urine” and native urine samples from healthy donors, as 
appropriate. For standard samples, we created a set of three standard 
GAG solutions at three different concentrations (low, medium, and 
high). We prepared the standard GAG solution at the “high” level by 
mixing the highest level of the calibrator sample for all disaccharides in 
milli-Q water. Next, we serially diluted the sample at the “high” level to 
“medium” and “low” levels (1 : 0.50 : 0.25 v/v) using Milli-Q water. For 
proxy urine samples, we prepared a “proxy urine” pool by mixing urine 
collected from healthy donors. Next, we depleted GAGs from the proxy 
urine pool by recovering the filtrate resulting from ultracentrifugation 
(14000 g at 9 ◦C for 60 min) in the filter provided in the kit. We spiked 
the standard GAG solution into the proxy urine at the beginning of 
sample preparation (before filtration) or immediately after filtration 
during sample preparation. For native urine samples, we sourced native 
urine from self-rated healthy adult donors and collected them in a 
polypropylene jar at room temperature. We kept samples frozen (-80 ◦C) 
until the analysis. The study was approved by the Ethical Committee 
(Etikprövningsmyndigheten) in Gothenburg, Sweden on February 8, 
2018 (#737-17). Further details on samples are provided in the SI 
Methods. 
3. Results 
3.1. Overview of the standardized kit method 
The kit – based on a previously described method illustrated in 
Fig. 1A [12] - consisted of a instructions-for-use protocol, reagents 
(including buffers and solvents), and consumable for sample preparation 
to extract free GAGs from frozen samples and subsequent MRM analysis 
for GAG detection and quantification using a UHPLC-MS/MS method. 
Seventeen disaccharides (8 for CS, 8 for HS, and HA) – here on referred 
to as analytes – could be independently and simultaneously measured 
with the kit. The kit included the standard solution and instructions to 
prepare a calibration curve for each analyte starting from the provided 
highest calibration level (the nominal concentration of the disaccharide 
at each calibration level was provided in Table S1); a mixture of 17 
purified disaccharides (one per analyte) to aid the operator in the 
adjustment of eventual drifts in retention times, and four quality control 
(QC) samples to be used in every MS run to monitor inter-sequence 
variability. In Fig. 1B, representative chromatograms are illustrated 
for the afore-mentioned mixture of 17 purified disaccharides quantified 
using the kit (see Fig. S1 for chromatograms derived from the standard 
GAG solution). 
We characterized the analytical performance of the kit in terms of 
calibration capability and performance in native human samples. 
3.2. Characterization of the kit analytical performance: Calibration 
First, we characterized the calibration curve parameters: linearity, 
detection capability, selectivity and specificity, accuracy and precision, 
carry-over, and disaccharide stability in the auto-sampler. This process 
established the performance of the calibration curve over a specific 
range for each disaccharide. 
In the second part, we performed the characterization of the kit in 
terms of GAGs extraction, detection, and quantification in native 
(human) samples by measuring the following parameters: selectivity 
and specificity, recovery, matrix effect, linearity response, accuracy and 
precision, and disaccharide stability. 
3.2.1. Linearity and detection capability of the calibrators 
We tested the linearity of the calibration curve for each disaccharide. 
We prepared nine levels of calibration of each disaccharide in triplicates, 
injecting each replicate two times. We pre-specified acceptance criteria 
for a level to be included in the final calibration curve in terms of 
acceptable coefficient of variation (CV), which was required to be lower 
than 25% (30% for the lowest level), and deviation with the respect to 
the nominal concentration after back-calculation, which was required to 
be lower than 25%. We defined the upper limit of quantification (ULoQ) 
and low limit of quantification (LLoQ) for each disaccharide as the 
highest and lowest calibration levels meeting the acceptance criteria, 
respectively. We defined the range the linearity as the concentration 
between LLoQ and ULoQ. 
In Table 1, we reported for each disaccharide the number of cali-
bration levels within the range of linearity between LLoQ and ULoQ, 
including the coefficient of determination (R2) of the calibration curve 
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and the coefficient of variation (CV) and deviation of back-calculated 
concentration with respect to the nominal concentration at the LLoQ 
and ULoQ. 
For 15 of 17 disaccharides (all except TriS CS and 2s6s HS), we ob-
tained a calibration curve with acceptable linearity and detection 
capability. In cases where the calibration curve could not be constructed 
(for TriS CS and 2s6s HS), GAG quantification relied on the ratio be-
tween the observed peak area and the corresponding peak area at the 
highest level of the provided calibrator. 
3.2.2. Selectivity and specificity of the calibrators 
We tested the selectivity and specificity to each disaccharide by 
inspecting the presence of peaks of an area >20% LLoQ for that disac-
charide in blank samples. For each disaccharide, no peak could be 
detected at the expected retention time for that disaccharide in any of 
the blank samples. Selectivity and specificity for the kit were therefore 
deemed acceptable for all disaccharides. 
3.2.3. Accuracy and precision of the calibrators 
We tested the accuracy and precision of the calibration curves by 
creating a set of three standard GAG solutions at three different con-
centrations (low, medium, and high). In Tables 2 and 3, we reported the 
accuracy (percentage difference between nominal concentration for a 
disaccharide in the standard GAG solution and measured concentration) 
over a 2-day experiment and the precision (as CV) for each disaccharide 
at each standard GAG solution concentration (low, medium, and high). 
The accuracy was acceptable for virtually all detected CS and HA 
disaccharides at all 3 concentrations on both Day 1 and Day 2, as well as 
for most detected HS disaccharides at medium and high concentrations 
on Day 1 (but not on Day 2). Similarly, both intraday and inter-day 
precision were acceptable for all detected CS and HA disaccharides at 
all 3 concentrations as well as for intraday precision for most detected 
HS disaccharides at all 3 concentrations. We attributed the results re-
ported in Tables 2 and 3 that did not meet the acceptance criteria to poor 
signal acquisition. 
3.2.4. Carry-over in the calibrators 
We tested the impact of the carry-over by inspecting the presence of 
peaks of an area >20% LLoQ for that disaccharide in blank samples 
immediately after the acquisition of the highest calibration curve level. 
For each disaccharide, no peak could be detected at the expected 
retention time for that disaccharide in any of the blank samples. Carry- 
over was therefore considered negligible for all disaccharides. 
Table 1 
Linearity of the calibration curve for each disaccharide including the number of calibrator levels, coefficient of determination (R2), and nominal concentration, co-
efficient of variation (CV), and deviation from back-calculated concentration for the lower limit of quantification (LLoQ) and upper limit of quantification (ULoQ). 
Acceptable values are marked in bold. Key: N.C. – not calibrated.  
Disaccharide N levels R2 LLoQ [µg mL− 1] LLoQ CV LLoQ deviation ULoQ [µg mL− 1] ULo CV ULoQ deviation 
0s CS 8 1.000 0.10 13% − 14% 5.33 2% − 1% 
2s CS 2 1.000 0.02 22 0 0.04 14 0 
4s CS 7 0.996 1.42 7 − 19 42.87 2 2 
6s CS 5 0.980 1.15 4 1 11.15 2 − 10 
4s6s CS 4 0.999 0.06 12 − 6 0.31 8 − 1 
2s4s CS 3 0.999 0.04 15 4 0.11 11 1 
2s6s CS 6 0.999 0.04 31 6 0.60 5 1 
TriS CS 0 N.C. N.C. N.C. N.C. N.C. N.C. N.C. 
HA 6 0.997 3.51 5 23 60.00 2 3 
0s HS 6 0.998 2.70 6 − 14 46.27 1 − 3 
2s HS 3 0.995 0.02 21 − 7 0.06 14 − 1 
6s HS 7 0.999 0.09 14 − 29 2.66 7 − 2 
Ns HS 6 0.996 0.48 10 − 16 8.20 6 − 4 
2s6s HS 0 N.C. N.C. N.C. N.C. N.C. N.C. N.C. 
Ns2s HS 3 0.999 0.46 26 2 1.44 20 0 
Ns6s HS 4 0.998 0.37 22 9 2.03 6 1 
TriS HS 2 1.000 0.24 21 0 0.43 39 0  
Table 2 
Accuracy (in terms of % deviation from nominal concentration in the standard 
GAG solution) at three concentration levels on two separate days. Acceptable 
values are marked in bold. Key: N.D. – not detected.  
Disaccharide Low Medium High  
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 
0s CS − 61% − 59% − 20% − 17% − 9% − 5% 
2s CS N.D. N.D. N.D. N.D. 100 79 
4 s CS 14 16 − 7 − 5 − 4 − 2 
6ss CS − 23 − 20 0 3 − 1 4 
2s4s CS N.D. N.D. − 4 1 − 6 5 
2s6s CS 1 − 5 1 1 2 4 
4s6s CS 1 − 3 3 0 2 3 
TriS CS N.D. N.D. N.D. N.D. N.D. N.D. 
HA − 27 − 22 − 12 − 9 − 3 0 
0 s HS 5 1 6 0 − 3 − 7 
2s HS N.D. N.D. 28 N.D. 8 − 49 
6s HS 4 − 29 13 − 21 3 − 30 
Ns HS − 18 − 31 − 1 − 14 0 − 12 
2s6s HS N.D. N.D. N.D. N.D. N.D. N.D. 
Ns2s HS N.D. N.D. 37 − 25 10 − 41 
Ns6s HS 26 8 19 4 12 − 2 
TriS HS N.D. N.D. N.D. N.D. 7 6  
Table 3 
Precision (in terms of CV% in the estimated concentration for each disaccharide 
in the standard GAG solution) at three concentration levels over two days. 
Acceptable values are marked in bold. Key: N.D. – not detected.  
Disaccharide Low Medium High  
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 
0s CS 2% 3% 4% 4% 3% 5% 
2s CS N.D. N.D. N.D. N.D. 224 416 
4s CS 2 3 1 2 3 3 
6s CS 1 3 1 3 3 5 
2s4s CS N.D. N.D. 15 17 8 14 
2s6s CS 12 13 6 6 8 8 
4s6s CS 13 12 8 10 7 7 
TriS CS N.D. N.D. N.D. N.D. N.D. N.D. 
HA 1 4 2 3 3 4 
0s HS 2 5 3 6 3 5 
2s HS N.D. N.D. 20 N.D. 18 41 
6s HS 8 26 9 29 7 26 
Ns HS 5 11 5 12 3 11 
2s6s HS N.D. N.D. N.D. N.D. N.D. N.D. 
Ns2s HS N.D. N.D. 36 58 22 40 
Ns6s HS 16 24 16 20 14 18 
TriS HS N.D. N.D. N.D. N.D. 20 22  
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3.2.5. Disaccharide stability in the autosampler 
We tested the stability of disaccharides stored in the autosampler at 
10 ◦C by monitoring the peak area of each analyte over 14 days at the 
third-highest calibration curve level for that disaccharide. In Table S2, 
we reported the change in peak areas for a given disaccharide at a given 
time point relative to the corresponding peak area at the initial time 
point. 
The stability in the auto-sampler of all disaccharides except Ns2s HS 
was acceptable over 6 days (at least 5 of 6-time points with < 30% de-
viation from Day 0). We found that all disaccharides except 4s CS had 
poor stability after 14 days in the autosampler. 
3.3. Characterization of the kit analytical performance: Concentration 
estimation 
Having established the performance of the calibration curve for each 
disaccharide, we could estimate disaccharide concentrations using the 
so-characterized calibration curves. In the second part, we, therefore, 
performed the characterization of the kit in terms of estimation of the 
disaccharide concentration in native samples by measuring the 
following performance parameters: selectivity and specificity, recovery, 
matrix effect, linearity response, accuracy, and precision and disaccha-
ride stability. For the sake of consistency, we chose human urine from 
healthy donors as the reference matrix for the native samples. 
3.3.1. Recovery 
We tested recovery by first generating a GAG-depleted sample 
(referred to as proxy urine, SI Methods); and next by spiking the proxy 
urine with a set of three standard GAG solutions at three different 
concentrations (low, medium, and high) either at the beginning of the 
sample preparation or immediately after filtration during sample prep-
aration. In Table S3, we reported the recovery of each disaccharide after 
filtration across five replicates. 
The results indicated acceptable recovery (<25% deviation) for all 
detectable CS disaccharides at all three concentration levels (except 2s 
CS, acceptable only at the highest level); for all detectable HS di-
saccharides at the “low” and “medium” concentration levels (except for 
2s HS); and for HA at the “medium” concentration level. 
3.3.2. Matrix effect 
We tested matrix effects to evaluate how endogenous compounds in 
native urine interfered with the measurement of the analytes. We spiked 
proxy urine from 6 healthy donors and milli-Q water samples in tripli-
cates with the above-described set of standard GAG solutions at two 
concentration levels, “high” and low”. In Table S4, we reported the 
matrix effect as the ratio (in %) between the disaccharide concentration 
in 6 proxy urine samples versus the milli-Q water sample at the two 
concentration levels, as well as the average matrix effect in proxy urine. 
The matrix effect was moderate (between 42% and 89%) in CS di-
saccharides at the “high” level and low (78% to 103%) at the “low” level, 
indicative of signal suppression due to matrix effects. We found 
moderate-to-high matrix effects in HA and HS disaccharides at the 
“high” level and moderate-to-low at the “low” level. 
3.3.3. Accuracy and precision in native samples 
We tested the accuracy of disaccharide concentrations in native 
samples by spiking the proxy with the same set of standard GAG solu-
tions as described above at three different concentration levels (low, 
medium, and high). In Table 4, we reported the accuracy in the con-
centration of each CS disaccharide in a three-day experiment by two 
operators on a given analysis day. We computed the intraday precision 
in terms of coefficient of variation from the same data and reported in 
Table 5. We then computed the intraday precision as the coefficient of 
variation from the same data and reported in Table 5. 
We were unable to reliably determine the accuracy and precision for 
HA and HS disaccharides because their estimated concentrations were 
close to the respective LLoQ even for the “high” level standard GAG 
solutions. We attributed this partly to matrix effects as later discussed. 
The accuracy in native samples was acceptable (<30% deviation 
from the nominal concentration) for all detectable CS disaccharides 
except for 0s CS, where the accuracy was below 70% in “medium” and 
“high” level samples - albeit never below 60%. The intraday precision in 
native samples was acceptable (CV < 25%) for all detectable CS 
disaccharides. 
3.3.4. Disaccharide stability in native samples 
We tested the stability of each disaccharide in the native matrix over 
14 days. Specifically, we prepared two proxy urine samples and spiked 
them with the above-described set of standard GAG solutions at two 
concentration levels (“high” and low”). We stored the spiked samples at 
− 20 ◦C and measured disaccharide concentrations on day 1 and day 14. 
In Table S5, we reported the percentage difference in the disaccharide 
concentration at a given level (“high” or “low” at Day 1 and Day 14 
compared to the corresponding nominal concentration. 
The stability in native samples was acceptable (<30% deviation from 
the nominal concentration) for all detectable CS disaccharides on Day 1 
and for 4 of 6 detectable CS disaccharides on Day 14, where the 
remaining two CS disaccharides (0s CS and 4s6s CS) deviated from the 
nominal concentrations between 33% and 37%, respectively. Note that 
the stability for HA and HS disaccharides could not be reliably estimated 
in this experiment and it was omitted. 
3.3.5. Selectivity and specificity in native samples 
We tested selectivity and specificity to each disaccharide by 
inspecting the presence of peaks of an area >20% LLoQ in proxy urine - 
without any spiked GAG solution. For each disaccharide, no peak could 
be detected in proxy urine at the expected retention time for that 
disaccharide. Selectivity and specificity in native samples were therefore 
acceptable for all disaccharides. 
3.3.6. Linearity in native samples 
We tested the linearity of disaccharide concentrations in native 
Table 4 
Accuracy of disaccharide concentration in proxy urine sample spiked at three concentration levels of a standard GAG solution over a three-day experiment by two 
operators. Note that accuracy for HA and HS disaccharides could not be reliably estimated in this experiment and it was omitted. Acceptable values marked in bold. 
Key: N.D. – not detected.  
Disaccharide Low Medium High  
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
0s CS 21% 20% 21% 31% 34% 31% 32% 34% 39% 
2s CS N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
4s CS 10 0 6 19 15 15 5 5 4 
6s CS 5 − 12 − 9 21 9 11 15 13 20 
2s4s CS N.D. N.D. N.D. N.D. N.D. N.D. 28 30 31 
2s6s CS 13 8 11 26 27 26 20 22 27 
4s6s CS 22 19 19 31 30 27 26 29 30 
TriS CS N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.  
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samples by spiking proxy with the set of standard GAG solutions as 
described above at nine different concentration levels. In Table 6, we 
reported the linearity for each disaccharide in terms of coefficient of 
determination (R2) for the linear regression between peak areas and 
concentration across the nine levels. 
The linearity was acceptable for all detectable CS disaccharides (R2 
> 0.95). Note that we were unable to reliably estimate the linearity for 
HA and HS disaccharides. 
3.4. External validation of kit analytical performance 
We sought to validate the hereby presented analytical performance 
specifications by performing tests of intra-laboratory and interlabor-
atory precision in a GLP-compliant external laboratory. 
3.4.1. Intra-laboratory precision 
We tested intra-laboratory precision by monitoring the disaccharide 
concentration in four QC samples included in the kit throughout 14 
independent experiments (runs). We used kits from the same lot for this 
experiment. We focused on the two properties of the GAG profile, non- 
sulfated CS (0s CS) and total CS, namely the sum of all measured CS 
disaccharides in a sample. Two QC samples were synthetic samples 
spiked with standard GAG solutions at high or low concentration 
(~14.5 µg mL− 1 and ~1.7 µg mL− 1 for total CS, respectively). The other 
two QC samples were native samples with known high or low total GAG 
concentration (~12.5 µg mL− 1 and ~4.2 µg mL− 1 for total CS, respec-
tively). In Fig. 2, the estimated concentration of the two key GAG 
properties (total CS and 0s CS) were plotted across runs. The concen-
trations for all measured CS GAGs were shown in Fig. S2. In Table S6, we 
reported the CV for each disaccharide in the 4 QC samples. 
The intra-laboratory precision was acceptable for all major CS 
disaccharides. The precision for HS disaccharides was acceptable only in 
“low” concentration samples, while for HA it was acceptable only in 
synthetic QC samples. In general, the concentration for di-sulfated and 
tri-sulfated disaccharides as well as 2s disaccharides was below LLoQ in 
all QC samples and therefore precision estimates should be interpreted 
with caution. 
3.4.2. Inter-laboratory precision 
We tested inter-laboratory precision by comparing the disaccharide 
concentration of two key GAG properties (total CS and 0s CS) in a panel 
of nine native urine samples from healthy donors independently 
analyzed in the reference laboratory versus the external laboratory. To 
limit the source of variability to inter-laboratory differences only, we 
used the same kit within one week in both laboratories. We found that 
the total CS and 0s CS concentration estimates from the reference lab-
oratory versus the external laboratory, were strongly correlated (Pear-
son correlation coefficient R > 0.95) (Fig. 3). 
4. Discussion 
GAGs are increasingly recognized as key molecular actors in mech-
anisms central to human physiology and pathology such as structural 
support within the extracellular matrix and regulation of cell signaling 
[2,24]. These mechanisms ultimately control phenotypes that, in dis-
ease, can culminate in physical and mental disabilities in mucopoly-
saccharidosis [4], jeopardize wound healing [25], promote cancer [26], 
lead to respiratory failure [3], or enable binding of viruses such as SARS- 
CoV-2 [10]. GAGs have therefore been proposed as potential biomarkers 
for these different diseases [4,27,28]. We and others have demonstrated 
the added advantage of measuring GAGs non-invasively, for example in 
blood and urine [5–8,29]. However, moving beyond biomarker dis-
covery to clinical translation necessitates the standardization of GAG 
measurements. UHPLC-MS/MS has emerged in the last decade as the 
gold standard for rapid quantification of GAG concentration and disac-
charide composition. Many methods were published that illustrated 
efficient separation of up to 19 disaccharides in biological samples 
[11–23]. However, none of these reported extensive analytical perfor-
mance testing. Therefore, here we comprehensively characterized the 
analytical performance of a kit for GAG measurements using an UHPLC- 
MS/MS method which has been previously described [12]. 
Overall, the kit efficiently separated 17 disaccharides and exhibited 
excellent selectivity and specificity to all disaccharides with negligible 
carryover and sufficient stability for typical laboratory work shifts. The 
calibrators were accurate and precise for 15 of 17 disaccharides over a 
range of concentrations covering approximately one-order of magnitude 
for each disaccharide. Notably, most above-cited methods appeared to 
rely on a single point of calibration for all disaccharides interrogated, 
thereby returning a relative concentration of each disaccharide in the 
sample (i.e. a mass fraction composition). Exceptions to these are the 
methods presented by Tomatsu et al. [16], which reported calibration 
curves for 7 disaccharides, and Yang et al. [23], which calibration curves 
Table 5 
Precision (in terms of CV%) of disaccharide concentration in proxy urine sample spiked at three concentration levels of a standard GAG solution over a three-day 
experiment by two operators. Note that precision for HA and HS disaccharides could not be reliably estimated in this experiment and it was omitted. Acceptable 
values marked in bold. Key: N.D. – not detected.  
Disaccharide Low Medium High  
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
0s CS 5% 7% 6% 3% 13% 12% 4% 6% 17% 
2s CS N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
4s CS 5 10 12 1 5 5 2 2 3 
6s CS 6 16 15 2 14 12 4 4 14 
2s4s CS N.D. N.D. N.D. N.D. N.D. N.D. 13 12 14 
2s6s CS 11 13 12 8 11 10 7 7 14 
4s6s CS 13 13 14 8 9 10 7 7 8 
TriS CS N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.  
Table 6 
Linearity of disaccharides in proxy urine 
samples (in terms of coefficient of determina-
tion R2 between peak areas and concentration 
levels) of a standard GAG solution serially 
diluted to generate nine concentration levels. 
Note that stability for HA and HS di-
saccharides could not be reliably estimated in 
this experiment and it was omitted. Accept-
able values marked in bold. Key: N.D. – not 
detected.  
Disaccharide R2 
0s CS 0.99 
2s CS 1.00 
4s CS 1.00 
6s CS 0.98 
2s4s CS 1.00 
2s6s CS 0.99 
4s6s CS 1.00 
TriS CS N.D.  
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for the same 17 disaccharides as those detected here. Compared to 
published methods, the here-characterized kit for absolute quantifica-
tion of free GAGs was found to be capable to calibrate as many as 15 
disaccharides simultaneously. 
In native samples, here using urine as the reference matrix, we 
demonstrated the robust and accurate analytical performance charac-
teristics of the kit. Critically for analyses of biological and clinical 
samples, the kit enabled the quantification of CS disaccharides within a 
calibration range that captured physiological values spanning one order 
of magnitude. We were unable to validate the results on HA and HS 
disaccharides because the concentrations recovered in urine were below 
the LLoQ for virtually all of these disaccharides. This could simply 
reflect a low abundance of urinary HA and HS in physiological condi-
tions compared to CS. The hypothesis is in line with previous reports in 
which the total HA and HS concentration in urine were measured as 
~20% of the total CS concentration, almost an order of magnitude less 
abundant [8,18]. Nevertheless, we could not rule out the hypothesis that 
the kit was underperforming in the quantification of HA and HS di-
saccharides in the urine. We attributed one possibility to the here- 
observed matrix effects, which showed moderate to strong peak area 
suppression in HA and HS in the urine. Another explanation could be a 
less efficient extraction yield during enzymatic digestion of HA and HS 
disaccharides as compared to CS disaccharides. Overall, we showed that 
the kit had an acceptable analytical performance for the quantification 
Fig. 2. Total CS and 0s CS concentration (in µg mL− 1) in 4 QC samples (in duplicates) across 14 runs in an external laboratory. The line represents the least square 
regression for disaccharide concentration across runs (shaded area represents 95% confidence interval on the regressed mean). 
Fig. 3. Inter-laboratory quantification robustness. The figure shows 0s CS and total CS concentration in 9 native urine samples from healthy donors as estimated in 
the reference laboratory (Lab #1) versus the external laboratory (Lab #2). The diagonal line represents the identity line. The Pearson correlation coefficient R for the 
correlation is displayed with its p-value (permutation test). 
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of CS disaccharides in native samples, while its performance in HA and 
HS warranted further investigation. 
We deemed the kit standardized for CS measurements given that the 
intra-laboratory and inter-laboratory precision tests produced accept-
able results across two independent laboratories. Specifically, the here- 
described kit proved capable to simultaneously calibrate 15 of 17 di-
saccharides with high linearity (R2 > 0.99 for all disaccharides except 6s 
CS wherein R2 = 0.98) and with high intra-laboratory precision using 14 
replicates of four control urine samples (CV ranging 8 to 22% at “high” 
concentration and 8 to 42% at “low” concentration for the major CS 
disaccharides, here defined as >5% of total CS). In comparison, Tomatsu 
et al. [16] reported a method that could quantify 7 disaccharides (2 
keratan sulfate disaccharides, 3 HS, and 2 CS) with linearity R2 ranging 
0.982 to 0.993 across two orders of magnitude and with an intra-assay 
precision CV ranging 2 to 15% using three control serum samples. 
Yang et al. [23] proposed a method for the quantification of 17 di-
saccharides (same as those detected by the kit here described) with 
linearity R2 ranging 0.976 to 0.999 across one order of magnitude - but 
no estimates on assay precision [23]. Wei et al. [17] described a method 
that could quantify 12 HS disaccharides in relative concentrations (mass 
fraction %) with an intra-assay precision CV ranging 1 to 21% for the 
major HS disaccharides (>5% of total HS) using one control serum 
sample. Overall, the kit had performance characteristics comparable 
with previously developed methods while extending the breadth of GAG 
quantification to 15 disaccharides. 
In conclusion, we verified the analytical performance of a kit for GAG 
disaccharide quantification using an LC/MS-MS method. The findings 
suggest that the kit had standardized characteristics for the absolute 
quantification of 15 disaccharides and precise and accurate quantifica-
tion of CS disaccharides in native samples. Noteworthy, the original 
method [12] can be extended to analyze protein-bound GAGs too with 
appropriate use of proteolytic agents (e.g. protease K). The kit did not 
include such agent and therefore it is theoretically limited to the protein- 
free fraction of GAGs in a sample. In principle, the protocol could be 
modified to measure protein-bound GAGs in more complex matrices 
(such as solid tissues) via addition of proteases. Future work should be 
directed towards the inclusion of disaccharides here omitted, for 
example, keratan sulfate disaccharides, and to improve the analytical 
performance in the quantification of HA and HS disaccharides in the 
urine. 
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